Medis laboratories invests in mental health since 2004. The first Medis psychiatric drug marketed in Tunisia is Fluoxetin under the name of Rosal. Rosal is indicated to treat the most clinical forms of depression. Thanks to its clinical good results, Rosal was rapidly adopted by psychiatrists in offices and hospitals.

 

Schizophrenia was selected by the WHO as mental heal world day theme in 2007. In the beginning of this year, Medis laboratories put at the disposal of the Tunisian patients suffering of schizophrenia, a new drug olanzapine based and marketed under the name of Vaincor.

 

Vaincor is a treatment of schizophrenia at its different stages since 18 years old. Vaincor is available in 5 and 10mg tablets.

The treatment is, generally, started at the dose of 10mg and then adjusted in accordance with the clinical state evolution. The dose can be increased till 20mg. besides of its efficiency in the different clinical aspects of schizophrenia, Vaincor is a well tolerated and with an affordable price tag.

 

Medis commitments to support health consist in much more than ensuring drugs quality and health economy, they aim to promote medical research. Medis prize for research in psychiatry is offered by Medis laboratories each year, to reward the best research performed in mental health field.